The rise and fall of drotrecogin alfa (activated)

The Lancet Infectious Diseases

Volumn 12, Issue 9, 2012, Pages 649-651

  Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

BLEEDING; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; SURVIVAL;

ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; MALE; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS;

EID: 84865302435     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70175-5     Document Type: Letter

References (14)

1. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. the Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group.
2. Vincent JL, Opal SM, Marshall JC Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions. Crit Care Med 2010, 38:283-287.
3. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332-1341. the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.
4. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369:836-843.
5. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366:2055-2064. the PROWESS SHOCK Study Group.
6. Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0·4 versus Ringer's acetate in severe sepsis. N Engl J Med 2012, published online June 27. 10.1056/NEJMoa1204242.
7. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010, 362:779-789.
8. Mosnier LO, Zlokovic BV, Griffin JH The cytoprotective protein C pathway. Blood 2007, 109:3161-3172.
9. Cao C, Gao Y, Li Y, Antalis TM, Castellino FJ, Zhang L The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest 2010, 120:1971-1980.
10. Kerschen E, Hernandez I, Zogg M, et al. Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest 2010, 120:3167-3178.
11. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007, 204:2439-2448.
12. Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009, 180:861-866.
13. Kalil AC, LaRosa SP Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis 2012, published online July 17. http://dx.doi.org/10.1016/S1473-3099(12)70157-3.
14. Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care 2012, 16:R14.